Inebilizumab

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Immunoglobulin G4-related Disease

Conditions

Immunoglobulin G4-related Disease

Trial Timeline

Apr 3, 2026 → Jun 10, 2031

NCT ID

NCT07222553

About Inebilizumab

Inebilizumab is a phase 2 stage product being developed by Amgen for Immunoglobulin G4-related Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07222553. Target conditions include Immunoglobulin G4-related Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06987539	Phase 2	Recruiting	Apr 30, 2026	Mar 13, 2030	Generalized Myasthenia Gravis
NCT07222553	Phase 2	Recruiting	Apr 3, 2026	Jun 10, 2031	Immunoglobulin G4-related Disease
NCT06180278	Approved	Active	Apr 2, 2024	Jun 26, 2028	Neuromyelitis Optica Spectrum Disorder
NCT05549258	Phase 2	Recruiting	Jul 3, 2023	Apr 13, 2027	Neuromyelitis Optica Spectrum Disorder
NCT04540497	Phase 3	Active	Dec 4, 2020	Oct 31, 2028	IgG4 Related Disease

Competing Products

11 competing products in Immunoglobulin G4-related Disease

See all competitors

Product	Company	Stage	Hype Score
ABBV-383 (Etentamig)	AbbVie	Phase 1/2	41
zigakibart	Novartis	Phase 2	52
iptacopan	Novartis	Phase 3	77
CCX168	Amgen	Phase 2	51
Rilzabrutinib + Placebo + Glucocorticoid	Sanofi	Phase 3	76
rilzabrutinib + Glucocorticoids	Sanofi	Phase 2	51
Felzartamab	Biogen	Phase 2	49
Felzartamab + Placebo	Biogen	Phase 3	74
Sparsentan	Travere Therapeutics	Phase 2	47
Sparsentan	Travere Therapeutics	Phase 2	47
sparsentan + irbesartan + Dapagliflozin	Travere Therapeutics	Phase 3	72

Other Products from Amgen